Skip to content

Turoctocog alfa

NovoEight (turoctocog alfa) is a protein pharmaceutical. Turoctocog alfa was first approved as NovoEight on 2013-11-13. It is used to treat factor VII deficiency, hemophilia a, hemorrhage, and von willebrand diseases in the USA. It has been approved in Europe to treat hemophilia a.
Trade Name NovoEight
Common Name Turoctocog alfa
Indication factor vii deficiency, hemophilia a, hemorrhage, von willebrand diseases
Drug Class
Turoctocog alfa
Get full access now